- Conditions
- Ovarian Cancer
- Interventions
- Nudge
- Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 2,050
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cerebrovascular Accident, Cancer, Coronary Arteriosclerosis, Heart Failure, Congestive, Diabetes Mellitus, Acquired Immunodeficiency Syndrome, Failure to Thrive, Pulmonary Disease, Chronic Obstructive, Dementia, Kidney Failure, Chronic, Pneumonia, Liver Failure, Renal Failure, Respiratory Failure, Stroke
- Interventions
- Multidisciplinary palliative care team met with patient
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer, Atypical Mesothelial Proliferation, Colorectal Cancer
- Interventions
- Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin, Doxorubicin, Hyperthermic Intraperitonial Chemotherapy, Cisplatin, Mitomycin C
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pancreatic Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma, Uterine Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Edward Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Naperville, Illinois
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Intermittent Fasting, Neoadjuvant chemotherapy
- Behavioral · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Ovarian Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Levonorgestrel, Placebo
- Other · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 66
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 46 more
- Conditions
- Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- ixabepilone
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Advanced Cancers
- Interventions
- Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- I-131-CLR1404
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin
- Conditions
- Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
- Interventions
- RO7515629, tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Nashville, Tennessee
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
- Biological · Drug · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
- Interventions
- Best Practice, Biospecimen Collection, Counseling, Discussion, Genotyping, Molecular Risk Assessment, Questionnaire Administration
- Other · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Salt Lake City, Utah
- Conditions
- Neoplasms, Ovarian
- Interventions
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Sacramento, California • San Francisco, California • Whittier, California + 7 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
- Interventions
- questionnaire administration, standard follow-up care, educational intervention
- Other · Procedure
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Hereditary Breast and Ovarian Cancer
- Interventions
- BRCA-Gist
- Behavioral
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Alexandria, Virginia • Richmond, Virginia
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- bryostatin 1, cisplatin, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
- Interventions
- Biospecimen Collection, Laboratory Biomarker Analysis, Lavage, Pap Smear
- Other · Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ovarian Cancer
- Interventions
- BCG vaccine, autologous tumor cell vaccine, carboplatin, cisplatin, cyclophosphamide, paclitaxel, dinitrophenyl, surgical procedure
- Biological · Drug · Other + 1 more
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 52 more
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- NY-ESO-1 OLP4, NY-ESO-1 OLP4 + Montanide, NY-ESO-1 OLP4 + Montanide + Poly-ICLC
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer
- Interventions
- mycophenolate mofetil, placebo
- Drug
- Lead sponsor
- Martin, Paul
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 15
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 11 more
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Sacramento, California • South Pasadena, California + 13 more
- Conditions
- Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor
- Interventions
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- Drug
- Lead sponsor
- Bio-Path Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Silver Spring, Maryland • Detroit, Michigan • Dallas, Texas + 1 more
- Conditions
- Ovarian Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Serous Tubal Intraepithelial Carcinoma, Early Detection of Ovarian Cancer
- Interventions
- Galleri Multi-Cancer Early Detection (MCED) Blood Test
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2039
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Interventions
- EMD 273066
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- Durate, California • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 1 more